Literature DB >> 15951971

The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families.

Ana Sánchez de Abajo1, Miguel de la Hoya, Javier Godino, Vicente Furió, Alicia Tosar, Pedro Pérez-Segura, Eduardo Díaz-Rubio, Trinidad Caldés.   

Abstract

The frame-shift mutation 1100delC in the cell-cycle-checkpoint kinase 2 gene (CHEK2) has been reported to be a low penetrance breast cancer gene in Northern European populations. However, the variant may be relevant for breast cancer risk in other populations, due to its low prevalence. Recent studies have proposed a role for the mutation in colorectal cancer, finding a strong association between the CHEK21100delC mutation and hereditary breast and colorectal cancer (HBCC). A previous study suggested that the CHEK21100delC variant was not of clinical relevance in Spanish breast/ovarian cancer families. Here, we demonstrate that this genetic variant is not of clinical relevance for HNPCC and HBCC Spanish families.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951971     DOI: 10.1007/s10689-004-5813-1

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  13 in total

1.  CHEK2 1100delC and colorectal cancer.

Authors:  O Kilpivaara; P Laiho; L A Aaltonen; H Nevanlinna
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

2.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.

Authors:  D W Bell; J M Varley; T E Szydlo; D H Kang; D C Wahrer; K E Shannon; M Lubratovich; S J Verselis; K J Isselbacher; J F Fraumeni; J M Birch; F P Li; J E Garber; D A Haber
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain.

Authors:  Trinidad Caldes; Javier Godino; Miguel de la Hoya; Iciar Garcia Carbonero; Pedro Perez Segura; Charis Eng; Manuel Benito; Eduardo Diaz-Rubio
Journal:  Int J Cancer       Date:  2002-04-10       Impact factor: 7.396

6.  Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Authors:  Hanne Meijers-Heijboer; Ans van den Ouweland; Jan Klijn; Marijke Wasielewski; Anja de Snoo; Rogier Oldenburg; Antoinette Hollestelle; Mark Houben; Ellen Crepin; Monique van Veghel-Plandsoen; Fons Elstrodt; Cornelia van Duijn; Carina Bartels; Carel Meijers; Mieke Schutte; Lesley McGuffog; Deborah Thompson; Douglas Easton; Nayanta Sodha; Sheila Seal; Rita Barfoot; Jon Mangion; Jenny Chang-Claude; Diana Eccles; Rosalind Eeles; D Gareth Evans; Richard Houlston; Victoria Murday; Steven Narod; Tamara Peretz; Julian Peto; Catherine Phelan; Hong Xiang Zhang; Csilla Szabo; Peter Devilee; David Goldgar; P Andrew Futreal; Katherine L Nathanson; Barbara Weber; Nazneen Rahman; Michael R Stratton
Journal:  Nat Genet       Date:  2002-04-22       Impact factor: 38.330

7.  The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Authors:  Rogier A Oldenburg; Karin Kroeze-Jansema; Jaennelle Kraan; Hans Morreau; Jan G M Klijn; Nicoline Hoogerbrugge; Marjolein J L Ligtenberg; Christi J van Asperen; Hans F A Vasen; Carel Meijers; Hanne Meijers-Heijboer; Truuske H de Bock; Cees J Cornelisse; Peter Devilee
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

Review 8.  Apparent Mendelian inheritance of breast and colorectal cancer: chance, genetic heterogeneity or a new gene?

Authors:  L Lipton; H J Thomas; R A Eeles; R S Houlston; M Longmuir; R Davison; S V Hodgson; V A Murday; C G Norbury; C Taylor; I P Tomlinson
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

9.  The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.

Authors:  Hanne Meijers-Heijboer; Juul Wijnen; Hans Vasen; Marijke Wasielewski; Anja Wagner; Antoinette Hollestelle; Fons Elstrodt; Renate van den Bos; Anja de Snoo; Grace Tjon A Fat; Cecile Brekelmans; Shantie Jagmohan; Patrick Franken; Paul Verkuijlen; Ans van den Ouweland; Pamela Chapman; Carli Tops; Gabriela Möslein; John Burn; Henry Lynch; Jan Klijn; Riccardo Fodde; Mieke Schutte
Journal:  Am J Hum Genet       Date:  2003-04-10       Impact factor: 11.025

10.  Frequency of CHEK2*1100delC in New York breast cancer cases and controls.

Authors:  Kenneth Offit; Heather Pierce; Tomas Kirchhoff; Prema Kolachana; Beth Rapaport; Peter Gregersen; Steven Johnson; Orit Yossepowitch; Helen Huang; Jaya Satagopan; Mark Robson; Lauren Scheuer; Khedoudja Nafa; Nathan Ellis
Journal:  BMC Med Genet       Date:  2003-01-15       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.